Technology Bundle ID: TAB-2642

Recombinant Pan-Lyssavirus for Use in Rabies and Broad-Lyssavirus Vaccination

Request More Info
Licensing Contact:
Primary Inventors: 
Xianfu Wu (CDC)
Co-Inventors: 
Charles Rupprecht (CDC), Ivan Kuzmin (CDC)
Therapeutic Area: 
Infectious Disease
Development Status: 

Pre-clinical

Institute or Center: 
CDC

CDC researchers have developed recombinant lyssaviruses that can be used for the development of an improved, broad-spectrum vaccine against several rabies genotypes. Lyssaviruses are single-stranded RNA viruses that cause rabies and rabies-like diseases in mammals. Currently, there are commercially available vaccines that are considered to be effective against infections from a single viral phylogroup; however, these vaccines confer little or no protection against viruses outside of the phylogroup. The present recombinants have glycoprotein-encoding genes from at least two different lyssaviruses and can be used as pan-lyssaviral vaccines to provide protection against infection by multiple lyssavirus phylogroups.

Applications:
  • Pan-lyssavirus vaccines
  • Rabies surveillance and vaccination programs
Advantages:
  • Broad-spectrum vaccine potential
  • Pan-lyssavirus vaccination tools will be particularly beneficial in endemic and developing regions
  • Employs a presently commercialized vaccine backbone/platform, making this innovation easily adaptable for industrial R&D and subsequent large-scale production

Patents

PCT Application PCT/US2011/041579
Filed on 2011-06-23
US Application 14/978,135
Filed on 2015-12-22
US Application 61/358,288
Filed on 2010-06-24
US Pat 9,248,179

Issued 2016-02-02

Publications

Kuzmin IV, et al.
PMID 18514350

Updated

Sep 17, 2013

Data Source: 
tts